WallStreetZen

NASDAQ: GERN
Geron Corp Stock Forecast, Predictions & Price Target

Analyst price target for GERN

Based on 1 analysts offering 12 month price targets for Geron Corp.
Min Forecast
$4.00+189.86%
Avg Forecast
$4.00+189.86%
Max Forecast
$4.00+189.86%

Should I buy or sell GERN stock?

Based on 1 analysts offering ratings for Geron Corp.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

GERN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Baird
Top 22%
79
BuyInitiates Coverage On$4.00+189.86%2021-11-02

1 of 1

Forecast return on equity

Is GERN forecast to generate an efficient return?
Company
-33.99%
Industry
21.88%
Market
37.5%
GERN's Return on Equity is forecast to be low in 3 years (-33.99%); analysts are not confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is GERN forecast to generate an efficient return on assets?
Company
-22.48%
Industry
6.66%
GERN is forecast to generate lower Return on Assets (-22.48%) than the US Biotechnology industry average (6.66%)
Forecast

GERN earnings per share forecast

What is GERN's earnings per share in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
-$0.36+5.88%
Avg 2 year Forecast
-$0.42+23.53%
Avg 3 year Forecast
-$0.37+8.82%

GERN revenue forecast

What is GERN's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$402.0k-0.25%
Avg 2 year Forecast
$400.0k-0.74%
Avg 3 year Forecast
$10.4M+2,480.65%
GERN's revenue is forecast to grow at an exceptional rate of 163.81% per year
Forecast

GERN revenue growth forecast

How is GERN forecast to perform vs Biotechnology companies and vs the US market?
Company
163.81%
Industry
30.03%
Market
10.08%
GERN's revenues are forecast to grow faster (163.81% per year) than the US Biotechnology industry average (30.03%)
Forecast
GERN's revenues are forecast to grow faster (163.81% per year) than the US market average (10.08%)
Forecast

Geron Corp Stock Forecast FAQ

Is Geron Corp Stock a good buy in 2021, according to Wall Street analysts?

The consensus among 1 Wall Street analysts covering (NASDAQ: GERN) stock is to Buy GERN stock.

Out of 1 analysts, 0 (0%) are recommending GERN as a Strong Buy, 1 (100%) are recommending GERN as a Buy, 0 (0%) are recommending GERN as a Hold, 0 (0%) are recommending GERN as a Sell, and 0 (0%) are recommending GERN as a Strong Sell.

What is GERN's earnings growth forecast for 2021-2023?

(NASDAQ: GERN) Geron Corp's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 6.78%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 14.37%.

Geron Corp's earnings in 2021 is -$107,882,000.On average, 4 Wall Street analysts forecast GERN's earnings for 2021 to be $-115,901,655, with the lowest GERN earnings forecast at $-122,340,636, and the highest GERN earnings forecast at $-109,462,674. On average, 4 Wall Street analysts forecast GERN's earnings for 2022 to be $-135,218,597, with the lowest GERN earnings forecast at $-177,071,973, and the highest GERN earnings forecast at $-106,243,184.

In 2023, GERN is forecast to generate $-119,121,145 in earnings, with the lowest earnings forecast at $-119,121,145 and the highest earnings forecast at $-119,121,145.

What is GERN's revenue growth forecast for 2021-2023?

(NASDAQ: GERN) Geron Corp's forecast annual revenue growth rate of 163.81% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.03%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 10.08%.

Geron Corp's revenue in 2021 is $403,000.On average, 3 Wall Street analysts forecast GERN's revenue for 2021 to be $129,423,514, with the lowest GERN revenue forecast at $113,648,011, and the highest GERN revenue forecast at $145,842,916. On average, 2 Wall Street analysts forecast GERN's revenue for 2022 to be $128,779,616, with the lowest GERN revenue forecast at $128,779,616, and the highest GERN revenue forecast at $128,779,616.

In 2023, GERN is forecast to generate $3,348,270,026 in revenue, with the lowest revenue forecast at $3,348,270,026 and the highest revenue forecast at $3,348,270,026.

What is GERN's forecast return on assets (ROA) for 2021-2024?

(NASDAQ: GERN) forecast ROA is -22.48%, which is lower than the forecast US Biotechnology industry average of 6.66%.

What is GERN's Price Target?

According to 1 Wall Street analysts that have issued a 1 year GERN price target, the average GERN price target is $4.00, with the highest GERN stock price forecast at $4.00 and the lowest GERN stock price forecast at $4.00.

On average, Wall Street analysts predict that Geron Corp's share price could stay at $4.00 by Nov 2, 2022. The average Geron Corp stock price prediction forecasts a potential downside of N/A from the current GERN share price of $1.38.

What is GERN's Earnings Per Share (EPS) forecast for 2021-2023?

(NASDAQ: GERN) Geron Corp's current Earnings Per Share (EPS) is -$0.34. On average, analysts forecast that GERN's EPS will be $-0.36 for 2021, with the lowest EPS forecast at $-0.38, and the highest EPS forecast at $-0.34. On average, analysts forecast that GERN's EPS will be $-0.42 for 2022, with the lowest EPS forecast at $-0.55, and the highest EPS forecast at $-0.33. In 2023, GERN's EPS is forecast to hit $-0.37 (min: $-0.37, max: $-0.37).

What is GERN's forecast return on equity (ROE) for 2021-2024?

(NASDAQ: GERN) forecast ROE is -33.99%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.